淋球菌对头孢菌素耐药的治疗应对措施

摘要/Abstract

摘要：

淋病是淋球菌感染引起的性传播疾病之一，对人类健康及社会经济发展均有较大的危害。近年来，由于治疗不当、患者有耐药基因等多种原因，淋球菌逐渐对青霉素、四环素、环丙沙星等抗菌药出现耐药。目前头孢菌素为治疗淋球菌感染的一线药物，随着头孢菌素的广泛应用，淋球菌对其敏感性逐渐降低，出现临床治疗淋病失败的病例。为了进一步控制淋病，应对淋球菌耐药现象，临床已出现联合治疗、替代疗法、新药研发等方案，以期为控制对头孢菌素耐药的淋病治疗提供应对策略。

Abstract:

Wang Xin, Su Xiaohong, Jiang Juan Department of Sexuallly Transmitted Disease, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China Corresponding author: Su Xiaohong, Email: suxh@ncstdlc.org 【Abstract】 Gonorrhea is a sexually transmitted disease caused by Neisseria gonorrhoeae, and substantially harms human health and socioeconomic development. Due to inappropriate treatment and the presence of drug resistance genes in patients, antibiotic resistance has emerged in Neisseria gonorrhoeae, such as resistance to penicillin, tetracycline, ciprofloxacin, or other antibiotics. Currently, extended-spectrum cephalosporins （ESCs） are the first-line treatment of gonococcal infection. With the wide use of ESCs, the sensitivity of Neisseria gonorrhoeae to ESCs has been decreasing gradually, and there have been reports on cases of treatment failure in clinical practice. In order to control gonorrhea and deal with drug resistance in Neisseria gonorrhoeae, combined therapy, alternative therapy and new drugs have been developed in clinic.

王鑫蒋娟苏晓红. 淋球菌对头孢菌素耐药的治疗应对措施[J]. 中华皮肤科杂志, 2016, 49(5): 367-371.

xin wang. Management of cephalosporin resistance in Neisseria gonorrhoeae[J]. Chinese Journal of Dermatology, 2016, 49(5): 367-371.

参考文献 34

［1］	Unemo M. Current and future antimicrobial treatment of gonorrhoea⁃ the rapidly evolving Neisseria gonorrhoeae continues to challenge［J］. BMC Infect Dis, 2015, 15: 364. DOI: 10.1186/s12879⁃015⁃1029⁃2.
［2］	Duncan S, Duncan CJ. The emerging threat of untreatable gonococcal infection［J］. N Engl J Med, 2012, 366（22）: 2136. DOI:10.1056/NEJMc1203138.
［3］	Jeverica S, Golparian D, Hanzelka B, et al. High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE （VT12⁃008911） against Neisseria gonorrhoeae isolates with various high⁃level antimicrobial resistance and multidrug resistance［J］. J Antimicrob Chemother, 2014, 69（7）: 1866⁃1872. DOI: 10.1093/jac/dku073.
［4］	Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin［J］. Sex Transm Infect, 2012, 88（1）: 6⁃8. DOI: 10.1136/sextrans⁃2011⁃050362.
［5］	Furuya R, Nakayama H, Kanayama A, et al. In vitro synergistic effects of double combinations of beta⁃lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae［J］. J Infect Chemother, 2006, 12（4）: 172⁃176. DOI: 10.1007/s10156⁃006⁃0445⁃Z.
［6］	Pereira R, Cole MJ, Ison CA. Combination therapy for gonorrhoea: in vitro synergy testing［J］. J Antimicrob Chemother, 2013, 68（3）: 640⁃643. DOI: 10.1093/jac/dks449.
［7］	Pettus K, Sharpe S, Papp JR. In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae［J］. Antimicrob Agents Chemother, 2015, 59（4）: 2443⁃2445. DOI:10.1128/AAC.04127⁃14.
［8］	Barbee LA, Soge OO, Holmes KK, et al. In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae［J］. J Antimicrob Chemother, 2014, 69（6）: 1572⁃1578. DOI: 10.1093/jac/dkt540.
［9］	Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of 2⁃drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea［J］. Clin Infect Dis, 2013, 56（11）: 1539⁃1545. DOI: 10.1093/cid/cit084.
［10］	Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea［J］. Clin Infect Dis, 2014, 59（8）: 1083⁃1091. DOI: 10.1093/cid/ciu521.
［11］	Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015［J］. MMWR Recomm Rep, 2015, 64（RR⁃03）: 1⁃137.
［12］	Bignell C, Fitzgerald M, Guideline Development Group, et al. UK national guideline for the management of gonorrhoea in adults, 2011［J］. Int J STD AIDS, 2011, 22（10）: 541⁃547. DOI: 10.1258/ijsa.2011.011267.
［13］	Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future［J］. Clin Microbiol Rev, 2014, 27（3）: 587⁃613. DOI: 10.1128/CMR.00010⁃14.
［14］	Rice LB. Will use of combination cephalosporin/azithromycin therapy forestall resistance to cephalosporins in Neisseria gonorrhoeae［J］. Sex Transm Infect, 2015, 91（4）: 238⁃240. DOI: 10.1136/sextrans⁃2014⁃051730.
［15］	Gose SO, Soge OO, Beebe JL, et al. Failure of azithromycin 2.0 g in the treatment of gonococcal urethritis caused by high⁃level resistance in California［J］. Sex Transm Dis, 2015, 42（5）: 279⁃280. DOI: 10.1097/OLQ.0000000000000265.
［16］	Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin［J］. Int J Infect Dis, 2011, 15（11）: e732⁃e739. DOI: 10.1016/j.ijid.2011.07.007.
［17］	Hauser C, Hirzberger L, Unemo M, et al. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates［J］. Antimicrob Agents Chemother, 2015, 59（3）: 1605⁃1611. DOI: 10.1128/AAC.04536⁃14.
［18］	Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta⁃analysis［J］. Postgrad Med J, 2013, 89（1049）: 142⁃147. DOI: 10.1136/postgradmedj⁃2012⁃050604rep.
［19］	Unemo M, Golparian D, Nicholas R, et al. High⁃level cefixime⁃ and ceftriaxone⁃resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure［J］. Antimicrob Agents Chemother, 2012, 56（3）: 1273⁃1280. DOI: 10.1128/AAC.05760⁃11.
［20］	Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea［J］. Antimicrob Agents Chemother, 2012, 56（7）: 3603⁃3609. DOI: 10.1128/AAC.00326⁃12.
［21］	Mayer C, Janin YL. Non⁃quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism［J］. Chem Rev, 2014, 114（4）: 2313⁃2342. DOI: 10.1021/cr4003984.
［22］	Charifson PS, Grillot AL, Grossman TH, et al. Novel dual⁃targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure⁃guided design and structure⁃activity relationships［J］. J Med Chem, 2008, 51（17）: 5243⁃5263. DOI: 10.1021/jm800318d.
［23］	Unemo M, Ringlander J, Wiggins C, et al. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 （AZD0914） among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014［J］. Antimicrob Agents Chemother, 2015, 59（9）: 5220⁃5225. DOI: 10.1128/AAC.00786⁃15.
［24］	Huband MD, Bradford PA, Otterson LG, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram⁃positive, fastidious Gram⁃Negative, and atypical bacteria［J］. Antimicrob Agents Chemother, 2015, 59（1）: 467⁃474. DOI: 10.1128/AAC.04124⁃14.
［25］	Jacobsson S, Golparian D, Alm RA, et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug⁃resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea［J］. Antimicrob Agents Chemother, 2014, 58（9）: 5585⁃5588. DOI: 10.1128/AAC.03090⁃14.
［26］	Jensen JS, Fernandes P, Unemo M. In vitro activity of the new fluoroketolide solithromycin （CEM⁃101） against macrolide⁃resistant and ⁃susceptible Mycoplasma genitalium strains［J］. Antimicrob Agents Chemother, 2014, 58（6）: 3151⁃3156. DOI: 10.1128/AAC.02411⁃14.
［27］	Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin （CEM⁃101） against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high⁃level antimicrobial resistance: potential treatment option for gonorrhea［J］. Antimicrob Agents Chemother, 2012, 56（5）: 2739⁃2742. DOI: 10.1128/AAC.00036⁃12.
［28］	Hook EW, Jamieson BD, Oldach D, et al. A phase II, dose ranging study to evaluate the efficacy and safety of single⁃dose oral solithromycin （CEM⁃101） for treatment of patients with uncomplicated urogenital gonorrhoea［J］. Sex Transm Infect, 2013, 89（Suppl 1）: A29⁃A30. DOI: 10.1136/sextrans⁃2013⁃051184.0093.
［29］	Hook EW 3rd, Golden M, Jamieson BD, et al. A phase 2 trial of oral solithromycin 1 200 mg or 1 000 mg as single⁃dose oral therapy for uncomplicated gonorrhea［J］. Clin Infect Dis, 2015, 61（7）: 1043⁃1048. DOI: 10.1093/cid/civ478.
［30］	Waites KB, Crabb DM, Duffy LB. Comparative in vitro suscep⁃tibilities of human mycoplasmas and ureaplasmas to a new investi⁃gational ketolide, CEM⁃101［J］. Antimicrob Agents Chemother, 2009, 53（5）: 2139⁃2141. DOI: 10.1128/AAC.00090⁃09.
［31］	Roblin PM, Kohlhoff SA, Parker C, et al. In vitro activity of CEM⁃101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia （chlamydophila） pneumoniae［J］. Antimicrobial Agents and Chemotherapy, 2010, 54（3）: 1358⁃1359. DOI: 10.1128/AAC.01343⁃09.
［32］	Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin （CEM⁃101） against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high⁃level antimicrobial resistance: potential treatment option for gonorrhea［J］. Antimicrob Agents Chemother, 2012, 56（5）: 2739⁃2742. DOI: 10.1128/AAC.00036⁃12.
［33］	Jacobsson S, Golparian D, Phan LT, et al. In vitro activities of the novel bicyclolides modithromycin （EDP⁃420, EP⁃013420, S⁃013420） and EDP⁃322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains［J］. J Antimicrob Chemother, 2015, 70（1）: 173⁃177. DOI: 10.1093/jac/dku344.
［34］	Biedenbach DJ, Turner LL, Jones RN, et al. Activity of JNJ⁃Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin⁃resistant strains［J］. Diagn Microbiol Infect Dis, 2012, 74（2）: 204⁃206. DOI: 10.1016/j.diagmicrobio.2012.06.006.